share_log

大成生化科技(00809)延迟刊发2021年经审核年度业绩

Dacheng Biotechnology (00809) delays the publication of audited annual results in 2021

Zhitong Finance ·  Mar 29, 2022 20:35

Zhitong Financial APP News, Dacheng biochemical Technology (00809) issued an announcement that due to the recent outbreak of COVID-19 in mainland China and Hong Kong, China, resulting in the flow of people, logistics and other restrictions, the Group's ability to collect and provide some necessary audit information on time was restricted, resulting in delays in the review process of the Group's annual results for the year ended December 31, 2021. The group's audit process was not completed on schedule. Due to the suspension of the Group's express delivery services in some major operating cities in mainland China and Hong Kong, China, as well as the quarantine or office closure of the Group's major operating facilities in Changchun, Harbin, Jinzhou and Shanghai, the receipt of the audit confirmation letter was delayed.

As at the date of this announcement, all necessary audit confirmations have been issued, but it is not currently possible for the Group to estimate the time for the collection of all necessary audit confirmations and information to complete the audit process, to enable the Group to publish its audited annual results for the year ended 31 December 2021. As a result, it is not expected that the Group will be able to publish its audited annual results for 2021 on or before 31 March 2022. The company will publish the unaudited annual results of the Group for the year ended December 31, 2022 on 31 March 2022.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment